Journals / KONURALP TIP DERGİSİ / 2021 / Cilt: 13 - Sayı: 2

Can Low Magnesium be A Rısk Factor for the Development of Polyneuropathy in Patıents With Diabetes?

Düşük Magnezyum Seviyeleri Tip 2 Diyabetli Hastalarda Polinöropati Gelişimi İçin Bir Risk Faktörü Olarak Ortaya Çıkabilir

Pages
169–174
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that an adequate magnesium level in patients with glycemic control can prevent the development of diabetic polyneuropathy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Changes in magnesium metabolism have a different effect on the metabolic and signaling pathways in the development and progression of diabetes.
📊
Key Findings & Data:This study aimed to determine the relationship between the serum magnesium level and polyneuropathy in patients with type 2 diabetes mellitus (DM).
💡
Conclusion & Impact:It was concluded that an adequate magnesium level in patients with glycemic control can prevent the development of diabetic polyneuropathy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetes mellitus · tip 2 · diyabetik polinöropati

Abstract

Objective: Changes in magnesium metabolism have a different effect on the metabolic and signaling pathways in the development and progression of diabetes. This study aimed to determine the relationship between the serum magnesium level and polyneuropathy in patients with type 2 diabetes mellitus (DM). Method: The study included type 2 DM patients who presented to the neurology outpatient clinic of Ankara City Hospital with the complaint of pain and burning sensation in the hands and feet and received a pre-diagnosis of polyneuropathy based on electroneuromyography (ENMG). Biochemistry and hormone parameters of patients were scanned retrospectively. Result: A total of 116 patients, 49 (42.2%) female and 67 (57.8%) male, were included in the study. When the patients were divided into three groups according to the tertiles of HbA1C, the frequency of polyneuropathy was significantly higher in the group with high HbA1C levels (P=0.004). A significant relationship was observed between the magnesium level and detection of polyneuropathy on ENMG The mean magnesium level was significantly lower in the polyneuropathy group(P=0.013). Patients with additional complications other than polyneuropathy had significantly lower magnesium levels than those without such complications (P=0.021). Conclusion: This study showed that the magnesium levels were significantly associated with the development of polyneuropathy in patients with type 2 DM. It was concluded that an adequate magnesium level in patients with glycemic control can prevent the development of diabetic polyneuropathy.

Özet

Amaç: Magnezyum metabolizmasındaki değişiklik, diyabetin gelişimi ve ilerlemesi üzerine metabolik ve sinyal yollarında farklı bir etkiye sahiptir. Bu çalışmanın amacı tip 2 Diabetes Mellitusu (DM) olan hastalarda serum magnezyum düzeyinin polinöropati üzerine ilişkisini belirlemektir. Metod: Bu çalışmaya Ankara Şehir Hastanesi nöroloji polikliniğine el ve ayaklarda ağrı ve yanma şikayeti ile başvurup polinöropati ön tanısıyla elektronöromiyografisi (ENMG) yapılan Tip 2 DM tanılı hastalar dahil edildi. Hastaların biyokimya ve hormon parametreleri retrospektif olarak tarandı. Bulgular: Çalışmaya 49 (%42,2)’u kadın, 67 (%57,8)’i erkek toplam 116 hasta dahil edildi. Hastaları HbA1C düzeylerini tertile göre 3 gruba ayırdığımızda, HbA1C değeri yüksek grupta nöropati görülme sıklığı anlamlı olarak daha fazlaydı (P=0,004). Magnezyum seviyesi ile ENMG’de polinöropati saptanma arasında anlamlı ilişki tespit edildi (P=0,013). Polinöropati dışında ek komplikasyonu olan hastaların magnezyum seviyeleri olmayanlara göre anlamlı derecede daha düşüktü (P=0,021). Sonuç: Bu çalışmada Tip 2 DM tanılı hastalarında polinöropati gelişimiyle magnezyum düzeylerinin anlamlı derecede ilişkili olduğunu göstermiştir. Glisemik kontrolü sağlanan hastalarda yeteli magnezyum seviyesinin diyabetik polinöropati gelişimini önleyebileceği sonucuna ulaşılmıştır.

🔖

Cite This Article

KÖSEM, A., AGADAYI, E., MUHURDAROGLU, M. (2022). Can Low Magnesium be A Rısk Factor for the Development of Polyneuropathy in Patıents With Diabetes?. KONURALP TIP DERGİSİ, Cilt: 13 - Sayı: 2, 169–174. https://ajindex.com/articles/575511

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518
  2. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10(2):393
  3. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care. 1988;11(1):34-40
  4. Siddiqui K, Bawazeer N, Joy SS. Variation in macro and trace elements in progression of type 2 diabetes. Scientific World Journal. 2014;461591
  5. Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in type 2 diabetes: A vicious circle? Diabetes. 2016;65(1):3–13
  6. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007;2(2):366–373
  7. Pokharel DR, Khadka D, Sigdel M, Yadav NK, Kafle R, Sapkota RM, et al. Association of serum magnesium level with poor glycemic control and renal functions in Nepalese patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2017;Suppl 1:417–423
  8. Agrawal P, Arora S, Singh B, Manamalli A, Dolia PB. Association of macrovascular complications of type 2 diabetes mellitus with serum magnesium levels. Diabetes Metab Syndr. 2011;5(1):41–44
  9. Wayner DD, Burton GW, Ingold KU, Locke S. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett. 1985;187(1):33–37
  10. Halliwell B. Albumin—an important extracellular antioxidant? Biochem Pharmacol. 1988;37(4):569–571
  11. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582(13):1783–1787
  12. Peng F, Yang Y, Liu J, Jiang Y, Zhu C, Deng X, et al. Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitisoptica. Eur J Neurol. 2012;19(2):277–283
  13. Ghafourifar P, Mousavizadeh K, Parihar MS, Nazarewicz RR, Parihar A, Zenebe WJ. Mitochondria in multiple sclerosis. Front Biosci. 2008;13:3116–3126
  14. Fuhua P, Xuhui D, Zhiyang Z, Ying J, Yu Y, Feng T, et al. Antioxidant status of bilirubin and uric acid in patients with myasthenia gravis. Neuroimmunomodulation. 2012;19(1):43–